AARTIPHARM Stock Overview
Aarti Pharmalabs Limited primarily engages in the manufacture and sale of active pharmaceutical ingredients (APIs) and pharmaceutical intermediates in India and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 3/6 |
| Financial Health | 5/6 |
| Dividends | 3/6 |
Aarti Pharmalabs Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹521.55 |
| 52 Week High | ₹566.95 |
| 52 Week Low | ₹320.30 |
| Beta | 0 |
| 1 Month Change | 19.77% |
| 3 Month Change | -2.29% |
| 1 Year Change | 43.11% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 80.94% |
Recent News & Updates
Estimating The Intrinsic Value Of Aarti Pharmalabs Limited (NSE:AARTIPHARM)
Apr 19
These 4 Measures Indicate That Aarti Pharmalabs (NSE:AARTIPHARM) Is Using Debt Reasonably Well
Mar 21Shareholder Returns
| AARTIPHARM | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | 4.6% | 2.3% | 2.6% |
| 1Y | 43.1% | 56.7% | 45.0% |
Return vs Industry: AARTIPHARM underperformed the Indian Pharmaceuticals industry which returned 57.2% over the past year.
Return vs Market: AARTIPHARM underperformed the Indian Market which returned 46.6% over the past year.
Price Volatility
| AARTIPHARM volatility | |
|---|---|
| AARTIPHARM Average Weekly Movement | 6.0% |
| Pharmaceuticals Industry Average Movement | 6.0% |
| Market Average Movement | 6.8% |
| 10% most volatile stocks in IN Market | 10.0% |
| 10% least volatile stocks in IN Market | 4.2% |
Stable Share Price: AARTIPHARM has not had significant price volatility in the past 3 months.
Volatility Over Time: AARTIPHARM's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2019 | 2,042 | Hetal Gala | www.aartipharmalabs.com |
Aarti Pharmalabs Limited primarily engages in the manufacture and sale of active pharmaceutical ingredients (APIs) and pharmaceutical intermediates in India and internationally. Its APIs and intermediates are used in various therapeutic areas, including anti-hypertensive, anti-asthmatic, anti-cancer, central nervous system (CNS) agents, skincare, decongestant, cardiovascular, anti-thalassemic, analgesic, anti-diabetic, and ophthalmologic medications. The company also develops new chemical entities (NCE), regulatory starting materials (RSM), basic starting materials, key starting materials (KSM), key building blocks, xanthine derivatives, and allied products.
Aarti Pharmalabs Limited Fundamentals Summary
| AARTIPHARM fundamental statistics | |
|---|---|
| Market cap | ₹47.27b |
| Earnings (TTM) | ₹1.95b |
| Revenue (TTM) | ₹18.32b |
24.3x
P/E Ratio2.6x
P/S RatioIs AARTIPHARM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AARTIPHARM income statement (TTM) | |
|---|---|
| Revenue | ₹18.32b |
| Cost of Revenue | ₹10.97b |
| Gross Profit | ₹7.34b |
| Other Expenses | ₹5.40b |
| Earnings | ₹1.95b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 21.46 |
| Gross Margin | 40.09% |
| Net Profit Margin | 10.62% |
| Debt/Equity Ratio | 13.1% |
How did AARTIPHARM perform over the long term?
See historical performance and comparison